The V2R antagonist tolvaptan, by inhibiting the binding of vasopressin to the receptor, promotes aquaresis and lowers cAMP synthesis, slowing progression of renal cysts also in humans as shown in randomized placebo-controlled clinical trials56–59. This evidence concerns the gene AVPR2 and cystic kidney disease.